In Silico Clinical Trials as a Strategic tool in Modern Drug Development
DOI:
https://doi.org/10.22270/ajprd.v13i5.1627Abstract
Medicine discovery and development are resource- ferocious processes, frequently hindered by high failure rates during clinical trials. In silico clinical trials( ISCTs) — computer- grounded simulations of mortal trials have surfaced as a transformative tool in ultramodern medicine development. By using computational models, real case data, and artificial intelligence, ISCTs enable the varification of medicine efficacy , safety, and optimal lozenge without risking mortal subjects. These simulations can induce virtual case populations, streamline trial designs, reduce costs, and ameliorate time- to- request effectiveness. ISCTs are particularly salutary in studying rare conditions, pediatric populations, and substantiated drug approaches. While promising, challenges similar as model confirmation, data quality, nonsupervisory acceptance, and ethical enterprises remain. With advancing technologies like AI, digital halves, and amount computing, ISCTs are poised to revise pharmaceutical exploration by offering safer, briskly, and further cost-effective pathways to medicine development..
Downloads
References
Michelson S, Sehgal A, Friedrich C. In silico prediction of clinical efficacy. Current opinion in biotechnology. 2006 Dec 1;17(6):666-70..
Chen B, Schneider LC, Röver C, Comets E, Elze MC, Hooker A, IntHout J, Jannot AS, Julkowska D, Mimouni Y, Savelieva M. In silico clinical trials in drug development: a systematic review. arXiv preprint arXiv:2503.08746. 2025 Mar 11.
Pappalardo F, Russo G, Tshinanu FM, Viceconti M. In silico clinical trials: concepts and early adoptions. Briefings in bioinformatics. 2019 Sep;20(5):1699-708..
Rohith. In silico clinical trials in drug development [Internet]. Pharma Focus Europe. 2025 Jun [cited 2025 Aug 19].
Available from: https://www.pharmafocuseurope.com/resea rch-development/in-silico-clinical-trialsindrug-development
Pappalardo F, Russo G, Tshinanu FM, Viceconti M. In silico clinical trials: concepts and early adoptions. Briefings in bioinformatics. 2019 Sep;20(5):1699-708..Alfonso S, Jenner AL, Craig M. Translational approaches to treating dynamical diseases through in silico clinical trials. Chaos: An Interdisciplinary Journal of Nonlinear Science. 2020 Dec 1;30(12).
In silico clinical trials [Internet]. Wikipedia. 2025 [cited 2025 Aug 29]. Available from: https://en.wikipedia.org/wiki/In_silico_clin ical_trials
Viceconti M, Pappalardo F, Rodriguez B, Horner M, Bischoff J, Tshinanu FM. In silico trials: Verification, validation and uncertainty quantification of predictive models used in the regulatory evaluation of biomedical products. Methods. 2021 Jan 1;185:120-7..
Arsène S, Parès Y, Tixier E, GranjeonNoriot S, Martin B, Bruezière L, Couty C, Courcelles E, Kahoul R, Pitrat J, Go N. In silico clinical trials: is it possible?.InHigh performance computing for drug discovery and biomedicine 2023 Sep 14 (pp. 51-99). New York, NY: Springer US.
In silico clinical trials [Internet]. Wikipedia; 2025 [cited 2025 Aug 29]. Available from: https://en.wikipedia.org/wiki/In_silico_clin ical_trials
IN-SILICO DRUG DESIGNING: REVOLUTIONIZING THE FUTURE OF… [Internet]. IBRI – Indian Biological Sciences and Research Institute; 2025 Apr 14 [cited 2025 Aug 29]. Available from: https://www.ibri.org.in/blog/in-silicodrugdesigning
Samei E. The future of in silico trials and digital twins in medicine. PNAS nexus. 2025 May;4(5):pgaf123.
Paliwal A, Jain S, Kumar S, Wal P, Khandai M, Khandige PS, Sadananda V, Anwer MK, Gulati M, Behl T, Srivastava S. Predictive Modelling in pharmacokinetics: from insilico simulations to personalized medicine. Expert Opinion on Drug Metabolism & Toxicology. 2024 Apr 2; 20(4):181-95.
Badano A. In silico imaging clinical trials: cheaper, faster, better, safer, and more scalable. Trials. 2021 Jan 19;22(1):64.
SNS Insider. In Silico Clinical Trials Market Size, Share & Growth Report 2032 [Internet]. [place of publication unknown]; [no date]. Available from: https://www.snsinsider.com/reports/insilicoclinical-trials-market-6369. Accessed 29 August 2025.
Roney M, Aluwi MF. The importance of insilico studies in drug discovery. Intelligent Pharmacy. 2024 Aug 1;2(4):578-9.
Ó Cathaoir K, Gefenas E, Hartlev M, Mourby M, Lekstutiene J, Lukaseviciene V. A European standardization framework for data integration and data-driven in silico models for personalised medicine – EUSTANDS4PM: Legal and ethical review of in silico modelling. Compact version. September 2020.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Kathale Ankita A, Khaire Rahul D, KoradePayal B, Sankhe Lochani D, Bhandare Tejashwini S, Ghuge Samiksha K
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
. 